Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.

IF 1.4 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Scottish Medical Journal Pub Date : 2022-02-01 Epub Date: 2022-02-11 DOI:10.1177/00369330221078995

Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, Savaş İsmail

{"title":"Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.","authors":"Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, Savaş İsmail","doi":"10.1177/00369330221078995","DOIUrl":null,"url":null,"abstract":"Background: Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.Aim: The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.Methods: We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.Results: A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.Conclusion: EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"67 1","pages":"18-27"},"PeriodicalIF":1.4000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scottish Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00369330221078995","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.

Aim: The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.

Methods: We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.

Results: A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.

Conclusion: EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估EBUS-TBNA细胞学样本中肺癌生物标志物谱以决定靶向治疗。

背景:指南推荐在非小肺细胞癌(NSCLC)患者中进行表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)、BRAF和ROS原癌基因-1(ROS1)基因和程序性死亡配体-1(PD-L1)蛋白表达的生物标志物检测。有研究报道，支气管内超声-经支气管针吸法(EBUS-TBNA)可以为癌症生物标志物分析提供足够的材料，但仍存在一些问题。目的:本研究的目的是评估EBUS-TBNA检测肺癌生物标志物的充分性。方法:回顾性分析2011年12月至2020年12月期间EBUS-TBNA检测EGFR、ALK、ROS-1、BRAF和PD-L1表达的非小细胞肺癌患者。结果:共有394名患者入组研究。EGFR突变和ALK融合是最常见的生物标志物。EGFR的EBUS-TBNA充分率为99.0%，ALK为99.1%，ROS1为97.2%，BRAF为100%，PD-L1为99.3%。多变量分析显示，组织学类型、非典型鳞状细胞白血病的治疗史、大小或样本病变的18-氟脱氧葡萄糖摄取与生物标志物检测的TBNA充分性没有任何关联。结论:EBUS-TBNA可为EGFR、ALK、ROS-1、BRAF、PD-L1等生物标志物的检测提供充足的材料。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Scottish Medical Journal 医学-医学：内科

CiteScore

4.80

自引率

3.70%

发文量

审稿时长

>12 weeks

期刊介绍： A unique international information source for the latest news and issues concerning the Scottish medical community. Contributions are drawn from Scotland and its medical institutions, through an array of international authors. In addition to original papers, Scottish Medical Journal publishes commissioned educational review articles, case reports, historical articles, and sponsoring society abstracts.This journal is a member of the Committee on Publications Ethics (COPE).